One to Watch - The next frontiers in innovative therapies
26 Aug 2022
Presented science not to be missed
The symposia programme at ESC Congress 2022 begins by highlighting how novel therapies may be used to treat some key areas of unmet need in cardiology. A session entitled ‘The next frontiers in innovative therapies’ is being held jointly with the International Society for Cardiovascular Translational Research (ISCTR) and is in keeping with their goal to expedite scientific discoveries into clinical applications.
Join ESC Past-President, Professor Jeroen Bax (Leiden University Medical Center - Leiden, Netherlands) and ISCTR Vice-President, Professor Anthony DeMaria (University of California San Diego - San Diego, USA) as they chair a star-studded symposium that provides a tour around a host of underserved CVDs where promising therapies are in development, with world-renowned speakers who have each contributed to the knowledge base in the area of their presentation.
The symposium starts with the journey from discovery to bedside by ISCTR President, Professor Nabil Dib (Mercy Gilbert Medical Center - Phoenix, USA). Following this, the audience will hear more about interventional solutions for heart failure from expert CV triallist, Professor JoAnn Lindenfeld (Vanderbilt University - Nashville, USA). Professor Ulf Landmesser (Charité University Hospital - Berlin, Germany) will then discuss the association between lipoprotein(a) and aortic valve stenosis and how this may be treated.
‘Can we eradicate atherosclerosis?’ is the title of the next presentation, given by Professor Eugene Braunwald (Brigham And Women's Hospital, Harvard Medical School - Boston, USA), known to many as the father of modern cardiology. Professor Ileana Pina (Thomas Jefferson University - Philadelphia, USA) will discuss innovations in heart failure with preserved ejection fraction, setting the scene for further ESC Congress presentations on new treatments for this disease. Professor Milind Desai (Cleveland Clinic Foundation - Cleveland, USA) will describe the current status of myosin inhibitors for the treatment of hypertrophic obstructive cardiomyopathy before the session ends with an interactive discussion. Why not join the conversation?